High doses of candesartan cilexetil on the reduction of proteinuria
Study identifier:D2452L00006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A double-blind, randomised, dose ranging, multi-centre, phase IIIb study to evaluate the efficacy and safety of high doses of candesartan cilexetil (Atacand®) on the reduction of proteinuria in the treatment of subjects with hypertension and moderate to severe proteinuria
Medical condition
Proteinuria
Phase
Phase 3
Healthy volunteers
No
Study drug
candesartan cilexetil
Sex
All
Actual Enrollment
270
Study type
Interventional
Age
18 Years - 80 Years
Date
Study Start Date: 01 Apr 2003
Primary Completion Date: -
Study Completion Date: 01 Dec 2006
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Kazi Borkowski
AstraZeneca
